OPHLF - Array: Poised For Growth
Since I have last written on Array (ARRY), the stock price has risen from $13.43 to $20.96 at the close of the market on 2/5/19. While this is a nice gain, the fundamentals of the company have also improved, suggesting there is much more room for this Mid-Cap biotech to run. While my last article largely focused on the collaborations and compounds Array has licensed out, here I will focus on the first two quarters of commercialization and the implications of expanding Braftovi® and Mektovi® into mutated BRAF (mBRAF) colorectal cancer ((CRC)).